Quanterix Corporation
NasdaqGM:QTRX Rapporto sulle azioni
Cap. di mercato: US$587.6m
Quanterix Performance dei guadagni passati
Il passato criteri di controllo 0/6 Gli utili di Quanterix sono diminuiti a un tasso medio annuo di -8.9%, mentre il settore Life Sciences ha visto gli utili crescere a un tasso medio annuo di 11.7%. I ricavi sono cresciuti crescere a un tasso medio annuo di 16.2%.
Informazioni chiave
-8.9%
Tasso di crescita degli utili
0.6%
Tasso di crescita dell'EPS
Life Sciences Crescita del settore 21.5% Tasso di crescita dei ricavi 16.2% Rendimento del capitale proprio -11.8% Margine netto -30.7% Ultimo aggiornamento sui guadagni 30 Jun 2024
Aggiornamenti sulle prestazioni recenti
Quanterix Corporation to Report Q3, 2024 Results on Nov 12, 2024 Nov 06
Quanterix Corporation to Report Q2, 2024 Results on Aug 08, 2024 Aug 01
First quarter 2024 earnings: EPS and revenues exceed analyst expectations May 09
Quanterix Corporation to Report Q1, 2024 Results on May 07, 2024 May 01
Full year 2023 earnings: EPS misses analyst expectations Mar 02
Quanterix Corporation to Report Q4, 2023 Results on Feb 27, 2024 Feb 17
Mostra tutti gli aggiornamenti
Quanterix Corporation Reaffirms Earnings Guidance for the Full Year 2024 Nov 13
Even With A 36% Surge, Cautious Investors Are Not Rewarding Quanterix Corporation's (NASDAQ:QTRX) Performance Completely Nov 07
Quanterix Corporation to Report Q3, 2024 Results on Nov 12, 2024 Nov 06
We're Hopeful That Quanterix (NASDAQ:QTRX) Will Use Its Cash Wisely Oct 17
Quanterix Corporation Appoints Jeffrey T. Elliott in Nominating and Governance Committee of the Board Oct 04
Quanterix Corporation Appoints Ivana Magovcevic-Liebisch to Board of Directors Oct 03
Quanterix Corporation Announces Commercialization of P-Tau 217 Test Kit Oct 01
Quanterix Corporation: Still Struggling To Gain Traction Aug 26
Quanterix Corporation Appoints Jeffrey Elliott to Its Board of Directors Aug 20
Take Care Before Jumping Onto Quanterix Corporation (NASDAQ:QTRX) Even Though It's 26% Cheaper Aug 15 Quanterix Corporation Revises Revenue Guidance for the Full-Year 2024 Aug 09
Quanterix Corporation to Report Q2, 2024 Results on Aug 08, 2024 Aug 01
Quanterix Corporation Presents Data Demonstrating Successful Multi-Marker Approach for Alzheimer’s Disease Detection that is More Effective than Standalone Plasma p-Tau 217 Jul 30
Positive Sentiment Still Eludes Quanterix Corporation (NASDAQ:QTRX) Following 25% Share Price Slump Jun 27
First quarter 2024 earnings: EPS and revenues exceed analyst expectations May 09
Quanterix Corporation Provides Earnings Guidance for the Full-Year 2024 May 08
Quanterix Corporation to Report Q1, 2024 Results on May 07, 2024 May 01
Price target decreased by 9.7% to US$29.80 Apr 19
New minor risk - Shareholder dilution Apr 17
Quanterix Corporation, Annual General Meeting, Jun 03, 2024 Apr 16
Quanterix Corporation's (NASDAQ:QTRX) 31% Cheaper Price Remains In Tune With Revenues Apr 14
Quanterix Corporation Announces Laurie Olson, Director Will Not Stand for Re-Election Apr 13
Quanterix (NASDAQ:QTRX) Is In A Strong Position To Grow Its Business Apr 05
Quanterix Corporation Receives Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease Mar 06
Quanterix Corporation (NASDAQ:QTRX) Yearly Results: Here's What Analysts Are Forecasting For This Year Mar 03
Full year 2023 earnings: EPS misses analyst expectations Mar 02
Quanterix Corporation Provides Earnings Guidance for the Year 2024 Mar 01
Quanterix Corporation Reaffirms Earnings Guidance for the Year 2023 Feb 27
Quanterix Corporation to Report Q4, 2023 Results on Feb 27, 2024 Feb 17
Price target increased by 11% to US$33.25 Jan 04
New minor risk - Shareholder dilution Nov 10
Quanterix Corporation Revises Earnings Guidance for the 2023 Nov 09
Quanterix Corporation Revises Earnings Guidance for the 2023 Nov 08
New major risk - Revenue and earnings growth Nov 08
Quanterix Corporation to Report Q3, 2023 Results on Nov 06, 2023 Oct 31
Quanterix Launches High Accuracy P-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer's Disease Oct 25
Here's Why We're Not Too Worried About Quanterix's (NASDAQ:QTRX) Cash Burn Situation Oct 12
Price target increased by 9.7% to US$31.00 Sep 27
Director recently bought US$502k worth of stock Sep 12
High number of new directors Sep 01
Quanterix Corporation Appoints William (Bill) P. Donnelly to its Board of Directors Aug 22
Consensus estimates of losses per share improve by 20% Aug 15 Quanterix Corporation Announces Michael Doyle Cease Serving as Treasurer, Effective August 21, 2023
Quanterix Corporation Provides Earnings Guidance for the Full-Year 2023 Aug 09
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 08
Quanterix Corporation to Report Q2, 2023 Results on Aug 08, 2023 Jul 23
Quanterix Corporation Launches LucentAD Biomarker Blood Test to Aid Physician Diagnosis of Alzheimer's Disease in Patients Jul 07
We're Not Very Worried About Quanterix's (NASDAQ:QTRX) Cash Burn Rate Jun 12
Consensus estimates of losses per share improve by 12% May 16
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 11
Price target increased by 11% to US$15.25 Apr 21
Full year 2022 earnings: Revenues and EPS in line with analyst expectations Mar 07
We Think Quanterix (NASDAQ:QTRX) Can Afford To Drive Business Growth Feb 10 Quanterix Corporation Appoints Brian Blaser to Board of Directors
Quanterix Corporation Simoa Technology Drives Advances in Alzheimer’s Disease Research Presented at 2022 Clinical Trials on Alzheimer’s Disease Conference Dec 06
Consensus forecasts updated Nov 16
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 10
Quanterix Corporation Reports Goodwill Impairment for the Third Quarter Ended September 30, 2022 Nov 09
Quanterix Corporation to Report Q3, 2022 Results on Nov 08, 2022 Nov 02
Quanterix Corporation: Selling For Less Than Cash Value Sep 28
We Think Quanterix (NASDAQ:QTRX) Can Afford To Drive Business Growth Sep 23
Quanterix Corporation Appoints Daniel Pikora as Chief Operating Officer Sep 10
Quanterix stock gains after insider buys reported by CEO and CFO Aug 17
Consensus forecasts updated Aug 15
Independent Director recently bought US$2.0m worth of stock Aug 13
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 09 Quanterix Corporation Announces the Resignation of Kevin Hrusovsky as Executive Chairman of Board of Directors
Quanterix Corporation to Report Q2, 2022 Results on Aug 08, 2022 Aug 02
Price target decreased to US$34.50 Aug 01
Quanterix Corporation Launches First pTau-181 Plasma Laboratory Developed Test for Clinical Diagnostic and Research Applications in the U.S Jul 28
Quanterix Corporation Announces Resignation of John Fry as General Counsel and Secretary, Effective August 12, 2022 Jun 26
President recently sold US$85k worth of stock Jun 16
Quanterix Announces Appointment of Karen A. Flynn to Board of Directors Jun 07
Quanterix Corporation Announces Resignation of Dawn Mattoon as Senior Vice President, Diagnostics, Effective July 10, 2022 May 20
Consensus forecasts updated May 17
Price target decreased to US$45.00 May 11
First quarter 2022 earnings: EPS and revenues exceed analyst expectations May 10
Quanterix Corporation to Report Q1, 2022 Results on May 10, 2022 May 04
Quanterix Corporation, Annual General Meeting, Jun 23, 2022 May 02
Quanterix Corporation Grants Breakthrough Device Designation from U.S. FDA for NfL Test for Multiple Sclerosis Apr 23 Quanterix Corporation announced that it has received funding from Alzheimers Drug Discovery Foundation Mar 31
We're Hopeful That Quanterix (NASDAQ:QTRX) Will Use Its Cash Wisely Mar 28
Consensus forecasts updated Mar 08 Quanterix Announces Executive Leadership Succession Plan, Effective April 25, 2022
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 03
Quanterix Corporation to Report Q4, 2021 Results on Mar 01, 2022 Feb 25
Is Quanterix (NASDAQ:QTRX) A Risky Investment? Feb 21
Insider recently sold US$98k worth of stock Feb 03
Insider notifies of intention to sell stock Jan 03
Ripartizione dei ricavi e delle spese
Come Quanterix guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate NasdaqGM:QTRX Ricavi, spese e utili (USD Millions ) Data Ricavi Guadagni Spese G+A Spese di R&S 30 Jun 24 129 -40 98 29 31 Mar 24 126 -36 96 27 31 Dec 23 122 -32 90 25 30 Sep 23 117 -39 87 23 30 Jun 23 112 -66 84 23 31 Mar 23 104 -85 88 24 31 Dec 22 106 -97 92 26 30 Sep 22 110 -98 102 28 30 Jun 22 111 -79 105 28 31 Mar 22 113 -66 99 28 31 Dec 21 111 -58 92 28 30 Sep 21 106 -47 83 26 30 Jun 21 110 -30 72 25 31 Mar 21 98 -30 65 23 31 Dec 20 86 -32 60 20 30 Sep 20 76 -33 55 18 30 Jun 20 60 -45 54 17 31 Mar 20 60 -43 53 17 31 Dec 19 57 -41 50 16 30 Sep 19 52 -39 47 16 30 Jun 19 47 -37 43 16 31 Mar 19 42 -34 38 16 31 Dec 18 38 -32 34 16 30 Sep 18 33 -30 29 16 30 Jun 18 28 -30 25 16 31 Mar 18 25 -31 22 16 31 Dec 17 23 -31 20 16 30 Sep 17 23 -31 17 19 30 Jun 17 21 -30 16 18 31 Mar 17 19 -30 14 18 31 Dec 16 18 -28 12 17 31 Dec 15 12 -20 10 10
Guadagni di qualità: QTRX al momento non è redditizia.
Margine di profitto in crescita: QTRX al momento non è redditizia.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: QTRX non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 8.9% all'anno.
Accelerare la crescita: Impossibile confrontare la crescita degli utili di QTRX nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia
Guadagni vs Settore: QTRX non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Life Sciences ( -4.7% ).
Rendimento del capitale proprio
ROE elevato: QTRX ha un Return on Equity negativo ( -11.79% ), in quanto al momento non è redditizio.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
